Revelation Biosciences, Inc. (REVB)

Revelation Biosciences Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	14.11	10.7	6.5	11.99	5.25	1.27
Cash & Short-Term Investments	14.11	10.7	6.5	11.99	5.25	1.27
Cash Growth	280.97%	64.64%	-45.80%	128.28%	312.09%	-98.28%
Other Current Assets	0.09	0.11	0.07	0.16	0.16	0.64
Total Current Assets	14.21	10.81	6.57	12.15	5.41	1.91
Net Property, Plant & Equipment	0.81	0.74	0.06	0.07	0.09	0.13
Other Long-Term Assets	0.03	0.03	-	-	-	-
Total Assets	15.04	11.58	6.62	12.21	5.5	2.04
Accounts Payable	0.83	0.58	0.78	1.36	0.55	0.6
Accrued Expenses	0.47	1.4	1.13	1.15	0.99	1.53
Current Portion of Leases	-	-	-	-	-	0.02
Other Current Liabilities	-	-	-	3.05	2.91	-
Total Current Liabilities	1.42	2	1.91	5.56	4.45	2.14
Long-Term Leases	0.64	0.72	-	-	-	-
Total Long-Term Liabilities	0.64	0.72	-	-	-	-
Total Liabilities	2.06	2.72	1.91	5.56	4.45	2.14
Common Stock	-	-	-	0	0	0
Additional Paid-in Capital	65.41	58.28	45.21	32.11	26.4	14.42
Retained Earnings	-52.43	-49.42	-40.51	-25.47	-25.35	-14.52
Total Common Shareholders' Equity	12.99	8.86	4.71	6.65	1.05	-0.1
Shareholders' Equity	12.99	8.86	4.71	6.65	1.05	-0.1
Total Liabilities & Equity	15.04	11.58	6.62	12.21	5.5	2.04
Total Debt	0.64	0.72	0	0	0	0.02
Net Cash (Debt)	13.48	9.98	6.5	11.99	5.25	1.26
Net Cash Growth	35.07%	53.51%	-45.80%	128.28%	317.57%	-98.30%
Net Cash Per Share	9.64	16.07	454.70	10101.08	13895.05	25691.73
Book Value	12.99	8.86	4.71	6.65	1.05	-0.1
Book Value Per Share	9.29	14.27	329.42	5599.65	2783.92	-2031.48
Tangible Book Value	12.99	8.86	4.71	6.65	1.05	-0.1
Tangible Book Value Per Share	9.29	14.27	329.42	5599.65	2783.92	-2031.48

Updated May 7, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q